retatrutide masld Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment Drug Pipeline for MASLD: What

The TRIUMPH 4 phase 3 trial reported a 28.7 percent average body weight loss at 68 weeks

Important Safety Information: Mounjaro carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies

10.1038/s41467-020-18751-8 49 KillworthH

The menopausal transition is characterised by markedly increased variability in menstrual cycle length and is usually divided into an early and late phase

Reduce Decision Fatigue : Having a plan in advance (like this guide) reduces the stress of making decisions when you feel terrible

Since insulin therapy often indicates more advanced disease progression, greater severity, or additional comorbidities, which may lead to a higher risk of intestinal obstruction, and there was no statistically significant difference in intestinal obstruction risk between GLP-1RAs and other anti-diabetic medications (e.g., SGLT2 inhibitors, metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors), the observed reduction relative to insulin does not necessarily suggest a protective effect of GLP-1RAs against intestinal obstruction